论文部分内容阅读
目的观察两种不同的新辅助化疗(NC)方案治疗局部晚期乳腺癌(LABC)的近期临床疗效及其毒副反应。方法选择2010年12月至2013年8月诊治的LABC患者60例,随机分为观察组30例和对照组30例。观察组采用TP方案(多西紫杉醇+吡柔比星)化疗,对照组采用CEF方案(环磷酰胺+表阿霉素+氟尿嘧啶)化疗,21 d为1个疗程,均化疗4个疗程。比较两组的近期疗效以及毒副反应。结果 (1)观察组临床有效率明显高于对照组(93.33%vs 73.33%,P<0.05);观察组降期率(40.00%)明显高于对照组(16.67%),两组降期率比较差异有统计学意义(P<0.05)。(2)两组不良反应主要有中性粒细胞减少、恶心呕吐、脱发、皮疹、腹泻、口腔黏膜炎、血小板计数减少、肝功能异常以及手足综合征。但对照组恶心、呕吐、血小板计数减少、肝功能异常发生率明显高于观察组,差异有统计学意义(P<0.05或P<0.01)。结论两种方案对LABC均有良好的效果,TP方案较CEF方案能更好地发挥其抗肿瘤效果,是一种安全有效的NC方案。
Objective To observe the recent clinical efficacy and toxicity of two different neoadjuvant chemotherapy (NC) regimens in the treatment of locally advanced breast cancer (LABC). Methods Sixty patients with LABC diagnosed and treated from December 2010 to August 2013 were randomly divided into observation group (30 cases) and control group (30 cases). The patients in the observation group were treated with TP (docetaxel + pirarubicin), while those in the control group were treated with CEF (cyclophosphamide + epirubicin + fluorouracil) chemotherapy for 21 days. Each was treated with 4 cycles of chemotherapy. Compare the short-term curative effect and side effect of two groups. Results (1) The clinical effective rate in the observation group was significantly higher than that in the control group (93.33% vs 73.33%, P <0.05). The reduction rate in the observation group (40.00%) was significantly higher than that in the control group (16.67% The difference was statistically significant (P <0.05). (2) The two groups of adverse reactions were mainly neutropenia, nausea and vomiting, hair loss, rashes, diarrhea, oral mucositis, reduced platelet count, abnormal liver function and hand-foot syndrome. However, the incidence of nausea, vomiting and platelet count and abnormal liver function in the control group were significantly higher than those in the observation group (P <0.05 or P <0.01). Conclusions Both of the two regimens have good effect on LABC. TP regimen can exert its anti-tumor effect better than CEF regimen, which is a safe and effective NC regimen.